Crossref
Revisiting CDK4/6 inhibition and SERDs: EMBER-3 and the path forward
AME Clinical Trials Review · 2026-04 · 4 · 19-19
DOI: 10.21037/actr-25-98 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-04. Verfasst von Carlos Henrique Barrios und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Barrios, C. H., & Reinert, T. (2026). Revisiting CDK4/6 inhibition and SERDs: EMBER-3 and the path forward. AME Clinical Trials Review, 4, 19-19. https://doi.org/10.21037/actr-25-98
Vancouver
Barrios CH, Reinert T. Revisiting CDK4/6 inhibition and SERDs: EMBER-3 and the path forward. AME Clinical Trials Review. 2026;4:19-19. doi:10.21037/actr-25-98
BibTeX
@article{Barrios2026,
author = {Barrios, Carlos Henrique and Reinert, Tomás},
title = {Revisiting CDK4/6 inhibition and SERDs: EMBER-3 and the path forward},
journal = {AME Clinical Trials Review},
year = {2026},
volume = {4},
pages = {19--19},
doi = {10.21037/actr-25-98}
}
EUVIMED